Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review
Vasiliki Michalarea(Royal Marsden Hospital), Maria Antonietta Bali(Royal Marsden NHS Foundation Trust), Ian Chau(Royal Marsden NHS Foundation Trust), Alvaro Ingles Garces(Royal Marsden NHS Foundation Trust), David Cunningham(Royal Marsden NHS Foundation Trust), Anja Williams(Sarah Cannon Research Institute), Elizabeth Smyth(National Health Service), Simona Picchia(Royal Marsden NHS Foundation Trust), Sheela Rao(Royal Marsden NHS Foundation Trust), Elisa Fontana(Sarah Cannon Research Institute)
Cited by 16
Related Papers
Gastric cancer
|The Lancet|2020|4.8k
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k